CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

Context Therapeutics Secures Full Rights to CT-202 Under Revised BioAtla Deal

PartnershipCT-202Positive
AI Analysis

Summary

Context Therapeutics has secured full rights to CT-202 under a revised agreement with BioAtla, expanding its drug portfolio through a licensing deal.

Importance:6/10
Sentiment:
0.50
licensingdealpartnershipdrug rights
Related Companies

Read the original article

Published by yahoo_finance on May 18, 2026 11:29 AM

Read Original